| Popis: |
Background: Cancer is a leading cause of death worldwide. Inhibiting mitosis is the most effective clinical technique for cancer treatment. The most critical field of medicinal chemistry and drug development research is the discovery of innovative anticancer drugs. Thiazolidine is a multifunctional nucleus with anticancer, anti-inflammatory, antioxidant, antibacterial, antifungal, antidiabetic, antihyperlipidemic, and antiarthritic properties. Methods: In this investigation, copper-nickel oxide nanoparticles synthesized by electrochemical synthesis yielded a significant yield. The capping was done with cetyltrimethyl ammonium bromide (CTAB), and the characterization was done with UV, FTIR, XRD, SEM-EDS, and TEM SAED. The biologically significant 2-(2-substituted-4-oxo-thiazolidine-3-yl)-1, 9-dihydro-purin-6-ones (GB-1 to GB-12) have been synthesized using copper-nickel oxide nanoparticles as a catalyst and by applying a microwave-assisted tool. It was characterized by melting point, IR, 1H NMR, 13C NMR and LC-HRMS/MS spectroscopy. Using Sulforhodamine B (SRB) test, all newly synthesized compounds were evaluated in vitro for anti-cancer, anti-inflammatory, antioxidant, and angiogenesis activities. Results: The compounds GB-6 (GI50: 30 μM), GB-8 (GI50: 10 μM) and GB-10 (GI50: 30 μM) exhibited significant cell growth inhibitory activity. The compounds GB-6, GB-8, GB-10 exhibited significant in vitro anti-inflammatory activity in the range of IC50:179.65-194.59 μg/ml as compared with aceclofenac (IC50:191.19μg/ml) and the antioxidant activity by DPPH radical scavenging assay the compounds GB-6 (IC50:11.96 µg/ml), GB-8 (IC50:10.67 µg/ml) and GB-10 (IC50: 9.08 µg/ml) exhibited excellent radical scavenging activities compared to ascorbic acid (IC50:13.04 µg/ml) and by the KMnO4 radical scavenging assay the compounds GB-2 (IC50:15.33 µg/ml), GB-4 (IC50:23.60 µg/ml), GB-8 (IC50:24.93 µg/ml), GB-10 (IC50:24.96 µg/ml) exhibited good radical scavenging activities compared to ascorbic acid (IC50: 26.55 µg/ml). The compounds GB-4, GB-8 and GB-10 at 10 nM test drug concentration and the GB-6 compounds at 100 nM test drug concentration show the maximum capillary growth inhibitory activity compared with thalidomide as a standard drug. Conclusion: Further development of anticancer drugs may be enabled by the discovery of related compounds to the anticancer agent, such as compound (GB-6), compound (GB-8), and compound (GB-10) as polo-like kinase 1 inhibitors. |
